Global Safety Monitoring Of Covid-19 Vaccine In Pharmacovigilance

[1]Shilanand Pattebahadur, [2]Shubham Vaidya
[1]Student, [2]Assistant Professor
[12]Department Of Pharmacy
[12]Sayali Charitable Trust's College Of Pharmacy Chhatrapati Sambhajinagar
[1]pharmacynotify1357@gmail.com, [2]vishvambarraut07@gmail.com

Abstract*—Pharmacovigilance (PV) and drug safety monitoring are essential components of healthcare systems aimed at ensuring the safe use of medicines. The primary goal of pharmacovigilance is to detect, assess, understand, and prevent adverse drug reactions (ADRs) and other drug-related problems. Continuous monitoring of medicines after their market release helps in identifying rare, delayed, or long-term side effects that may not be observed during clinical trials. The rapid development and worldwide administration of COVID-19 vaccines created an urgent need for strong global pharmacovigilance systems to monitor vaccine safety. Pharmacovigilance plays a critical role in detecting, assessing, understanding, and preventing adverse events following immunization (AEFIs). This research paper explores the global safety monitoring mechanisms established for COVID-19 vaccines and evaluates the effectiveness of international pharmacovigilance programs during the pandemic. Data from regulatory agencies, healthcare organizations, spontaneous reporting systems, and real-world evidence studies were reviewed to identify common adverse reactions, rare safety signals, and risk management strategies associated with different COVID-19 vaccines. The study highlights the contribution of organizations such as World Health Organization, national regulatory authorities, and vaccine surveillance databases in ensuring vaccine safety and maintaining public confidence. Furthermore, the paper discusses challenges including underreporting, misinformation, data inconsistency, and the need for advanced digital monitoring technologies. The findings indicate that continuous global collaboration and active pharmacovigilance significantly improved the detection of rare adverse events and supported evidence-based regulatory decisions. Strengthening international vaccine safety networks and integrating artificial intelligence with pharmacovigilance systems may enhance preparedness for future public health emergencies. This study emphasizes that effective global safety monitoring is essential for ensuring vaccine safety, improving public trust, and supporting successful immunization programs worldwide.

***Index Terms*—COVID-19 Vaccine, Pharmacovigilance, Vaccine Safety, Adverse Events Following Immunization (AEFI), Global Safety Monitoring, Drug Safety Surveillance, Vaccine Surveillance Systems, Public Health, Signal Detection, Risk Management, Vaccine Adverse Reactions, Post-Marketing Surveillance, Healthcare Regulatory Agencies, Immunization Programs, Real-World Evidence**

I. Introduction

The emergence of the coronavirus disease 2019 (COVID-19) pandemic created an unprecedented global public health crisis, leading to millions of infections and deaths worldwide. In response to this emergency, several COVID-19 vaccines were rapidly developed, authorized, and distributed across different countries to reduce disease transmission, hospitalization, and mortality. Although these vaccines demonstrated high efficacy and acceptable safety profiles during clinical trials, continuous monitoring of

their safety after large-scale administration became essential. This highlighted the importance of pharmacovigilance in ensuring vaccine safety and protecting public health.

Pharmacovigilance refers to the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other vaccine- or drug-related problems. During the COVID-19 vaccination campaign, global pharmacovigilance systems played a vital role in monitoring adverse events following immunization (AEFIs), identifying rare side effects, and supporting evidence-based regulatory decisions. International organizations such as the World Health Organization, along with national regulatory authorities and healthcare institutions, established enhanced vaccine safety surveillance programs to collect and analyze safety data in real time.

The rapid administration of billions of vaccine doses worldwide presented both opportunities and challenges for pharmacovigilance systems. Various reporting databases, including spontaneous reporting systems, electronic health records, and active surveillance networks, were utilized to detect potential safety signals associated with different COVID-19 vaccines. Commonly reported adverse effects included fever, fatigue, headache, and injection-site reactions, while rare events such as myocarditis, thrombosis with thrombocytopenia syndrome, and allergic reactions required detailed investigation and regulatory attention. Continuous safety monitoring helped maintain transparency, strengthen public confidence, and ensure that the benefits of vaccination outweighed potential risks.

Despite significant advancements, global pharmacovigilance efforts faced challenges such as underreporting of adverse events, variations in reporting standards among countries, misinformation on social media, and limited healthcare resources in developing regions. These challenges emphasized the need for stronger international collaboration, improved digital reporting technologies, and advanced analytical tools for effective vaccine safety monitoring. The integration of artificial intelligence, big data analytics, and real-world evidence has further improved the efficiency of modern pharmacovigilance practices.

This research paper aims to examine the role of global pharmacovigilance systems in monitoring the safety of COVID-19 vaccines, evaluate the effectiveness of current surveillance strategies, and discuss the challenges and future directions of vaccine safety monitoring during public health emergencies.

II. Review of Literature

- According to Annette Rudolph and colleagues, the COVID-19 vaccination campaign created unprecedented challenges for global PV systems due to the huge volume of adverse event reports and rapid deployment of vaccines. The researchers emphasized that international collaboration and advanced signal detection systems became essential for identifying vaccine-related risks. (Annette Rudolph ,Joseph Mitchell , Jim Barrett, Qun-Ying Yue)

- The World Health Organization established global vaccine safety monitoring systems through the WHO Programme for International Drug Monitoring and VigiBase. WHO collaborated with national regulatory agencies to monitor myocarditis, thrombosis with thrombocytopenia syndrome (TTS), and other vaccine-related adverse events

  (Qun-Ying Yue , Pinelopi Lundquist)

- European Medicines Agency (EMA) Safety Monitoring:European Medicines Agency implemented enhanced pharmacovigilance strategies during COVID-19. The EMA used EudraVigilance databases for signal detection and real-time safety monitoring of vaccines such as Pfizer-BioNTech, Moderna, AstraZeneca, and Janssen vaccines.

(Julie Durand , Jean-Michel Dogné , Georgy Genov , Catherine Cohet)

- Artificial Intelligence and Data Science in COVID-19 PV:Several researchers explored the role of machine learning and Bayesian statistical models in improving COVID-19 vaccine safety monitoring. Advanced computational methods helped detect true safety signals while reducing false-positive reports. (Bangyao Zhao ,Lili Zhao , Zhaoyue Sun , Byron C. Wallace)
- Safety of mRNA Vaccines :Researchers highlighted that mRNA vaccines represented a major advancement in vaccine technology. Continuous PV monitoring demonstrated that although rare adverse effects occurred, mRNA vaccines remained generally safe and highly effective against severe COVID-19 infection. (Halie M. Rando, Anthony Gitter , Casey S. Greene)
- Many authors highlighted the contribution of active surveillance systems and real-world evidence in strengthening pharmacovigilance activities. Electronic health records, mobile health applications, and digital monitoring platforms improved the collection of large-scale safety data. Researchers observed that real-world studies provided valuable information regarding vaccine safety in different age groups, pregnant women, Several literature reviews discussed the challenges faced by pharmacovigilance systems during the pandemic. Underreporting of adverse events, inconsistent reporting methods among countries, lack of awareness among healthcare professionals, and misinformation on social media were identified as major limitations affecting vaccine safety monitoring. Some researchers also pointed out that developing countries experienced difficulties in establishing efficient pharmacovigilance infrastructures due to limited technical and financial resources.
- immunocompromised patients, and individuals with comorbidities.
- Recent studies emphasized the growing role of artificial intelligence, machine learning, and big data analytics in modern pharmacovigilance practices. These technologies improved signal detection, data analysis, and rapid identification of rare adverse events. Researchers suggested that integrating advanced digital technologies with global pharmacovigilance networks could strengthen preparedness for future pandemics and improve public health responses.
- Overall, the reviewed literature indicates that global pharmacovigilance systems significantly contributed to monitoring the safety of COVID-19 vaccines and ensuring public confidence in

vaccination programs. Continuous improvement in reporting systems, international cooperation, and technological innovation remain essential for enhancing vaccine safety surveillance worldwide.

III. Overview of COVID-19 Vaccines

COVID-19 Vaccines

COVID-19 vaccines are biological preparations designed to stimulate the immune system to recognize and fight SARS-CoV-2 infection. These vaccines help the body develop immunity by producing antibodies and activating immune cells without causing the disease itself.

Several vaccines received Emergency Use Authorization (EUA) and later full approvals from regulatory agencies after extensive clinical trials demonstrated their safety and efficacy.

Types of COVID-19 Vaccines

1. mRNA Vaccines

mRNA vaccines use messenger RNA to instruct cells to produce the spike protein of SARS-CoV-2, triggering an immune response.

Examples:

1 Pfizer-BioNTech COVID-19 Vaccine

2 Moderna COVID-19 Vaccine

Advantages:

- High efficacy
- Rapid development
- Strong immune response

2. Viral Vector Vaccines

These vaccines use a harmless virus (vector) to deliver genetic material coding for the coronavirus spike protein.

Examples:

[1] Oxford-AstraZeneca COVID-19 Vaccine

[2] Johnson & Johnson COVID-19 Vaccine

[3] Sputnik V

3. Inactivated Vaccines

Inactivated vaccines contain killed SARS-CoV-2 virus particles that cannot cause disease but can stimulate immunity.

Examples:

TABLE I. Covaxin

TABLE II. Sinopharm COVID-19 Vaccine

TABLE III. CoronaVac

4. Protein Subunit Vaccines

These vaccines contain purified pieces of viral proteins that stimulate an immune response.

Example:

Fig. 1. Novavax COVID-19 Vaccine

- **Mechanism of Action**

COVID-19 vaccines work by exposing the immune system to viral antigens, mainly the spike protein of SARS-CoV-2. This exposure stimulates the production of antibodies and memory immune cells. If the vaccinated individual is later exposed to the actual virus, the immune system can recognize and neutralize it quickly, reducing the severity of infection.

Importance of COVID-19 Vaccination

COVID-19 vaccination played a major role in controlling the pandemic by:

[1] Reducing transmission of the virus

[2] Preventing severe disease and hospitalization

[3] Lowering mortality rates

[4] Protecting vulnerable populations

[5] Supporting herd immunity

[6] Helping restore social and economic activities

Safety and Effectiveness

Before approval, COVID-19 vaccines underwent preclinical studies and multiple phases of clinical trials to evaluate their safety, efficacy, and quality. After authorization, continuous monitoring through pharmacovigilance systems was conducted globally to identify rare adverse events and ensure ongoing vaccine safety.

Common side effects included:

- Fever

- Fatigue
- Headache
- Pain at injection site
- Muscle aches

Serious adverse events were rare and were continuously monitored by global health authorities.

IV. Vaccination Global Programs

Governments and international organizations launched mass immunization programs to ensure vaccine accessibility worldwide. Initiatives such as COVAX aimed to provide equitable vaccine distribution, especially to low- and middle-income countries.

COVID-19 Vaccine Market Outlook 2031

- The industry was valued at US$ 92.6 Bn in 2021
- It is projected to record CAGR of -13.6 from 2022 to 2031 to reach more than US$ 9.9 Bn by the end of 2031



Market Introduction

COVID-19 vaccines are medical products designed to protect individuals from the novel coronavirus (SARS-CoV-2) that causes COVID-19. The vaccines work by teaching the immune system to recognize and fight the virus, thereby reducing the risk of severe illness or death from COVID-19. Several different COVID-19 vaccines have been developed and authorized for emergency use around the world, including vaccines developed by Pfizer-BioNTech, Moderna, AstraZeneca-Oxford, Johnson & Johnson, and others. mRNA and viral vector vaccines are the major types of COVID vaccines. These vaccines use different technologies, such as messenger RNA (mRNA) and adenovirus vectors, to instruct the body to produce an immune response against the virus. Vaccines have undergone rigorous testing in clinical trials to ensure their safety and efficacy. Trials have shown that vaccines are highly effective at preventing severe illness and death caused by COVID-19, and they have been authorized for use by regulatory bodies around the world. Vaccines are being distributed globally to protect as many people as possible from the virus and to help bring an end to the pandemic.



graph displaying the proportions of the overall population who had received part (1st vaccine) or completed (2nd vaccine) a COVID-19 vaccination course by the end of 2021, stratified into World Trade Organization income categories. Dark green, completed course; Light green, partially vaccinated. Total proportion who have received any vaccine is stated at top of each bar. Data from Our World in Data—timepoint 31/12/21

V. Pharmacovigilance: Concepts and Principles

Introduction

Pharmacovigilance is an important branch of healthcare science that deals with the monitoring, detection, assessment, understanding, and prevention of adverse effects associated with medicines and vaccines. During the COVID-19 pandemic, pharmacovigilance became essential because COVID-19

vaccines were developed and distributed rapidly across the world. Continuous monitoring of vaccine safety helped ensure that the vaccines remained safe and effective for public use.

The global vaccination campaign against COVID-19 required strong pharmacovigilance systems to identify rare adverse events, assess risks, and maintain public confidence in immunization programs.

Definition of Pharmacovigilance

According to the World Health Organization, pharmacovigilance is defined as:

"The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problems."

In the case of COVID-19 vaccines, pharmacovigilance focuses on monitoring vaccine safety and identifying Adverse Events Following Immunization (AEFI).

Concept of Pharmacovigilance in COVID-19 Vaccines

The concept of pharmacovigilance for COVID-19 vaccines is based on continuous safety surveillance throughout the vaccine life cycle. Since vaccines were introduced under emergency use authorization, post-marketing surveillance became necessary to monitor their long-term safety and effectiveness in real-world populations.

Pharmacovigilance systems collect data from healthcare professionals, patients, vaccine manufacturers, and regulatory agencies. The collected data are analyzed to detect safety signals and evaluate whether reported adverse events are related to vaccination.

Main Concepts Include:

- Continuous vaccine safety monitoring
- Detection of adverse events
- Risk assessment and management
- Signal detection and evaluation
- Benefit–risk analysis
- Safety communication to the public
- Global collaboration among health organizations

Importance of Pharmacovigilance

Pharmacovigilance plays a major role in public health by ensuring safe vaccine use and protecting populations from potential harm.

Importance in COVID-19 Vaccination:

- Detects rare and serious adverse reactions
- Ensures vaccine quality and safety
- Supports regulatory decision-making
- Reduces vaccine-related risks
- Maintains public confidence in vaccination programs
- Helps control misinformation and vaccine hesitancy

Principles of Pharmacovigilance

1. Detection of Adverse Events

The first principle involves identifying any medical event occurring after vaccination. Reports are collected through national and international reporting systems.

2. Assessment of Causality

Pharmacovigilance experts evaluate whether the adverse event is directly related to the vaccine or occurred coincidentally.

3. Signal Detection

A safety signal refers to information suggesting a new possible association between a vaccine and an adverse effect. Statistical methods and data analysis are used for signal detection.

4. Risk–Benefit Assessment

The benefits of vaccination are continuously compared with potential risks. COVID-19 vaccines showed greater benefits in preventing severe disease and death than the risks of rare adverse reactions.

5. Risk Management

Appropriate strategies are developed to minimize identified risks and improve vaccine safety.

6. Communication and Transparency

Accurate safety information should be communicated clearly to healthcare professionals and the public to maintain trust in vaccines.

7. Continuous Monitoring

Pharmacovigilance is an ongoing process that continues even after vaccine approval and widespread use.

Adverse Events Following Immunization (AEFI)

AEFI refers to any undesirable medical occurrence after immunization that may or may not be caused by the vaccine.

Types of AEFI:

1. Vaccine product-related reaction
2. Vaccine quality defect-related reaction
3. Immunization error-related reaction
4. Anxiety-related reaction
5. Coincidental event

Methods Used in COVID-19 Vaccine Pharmacovigilance

Passive Surveillance

Healthcare providers and patients voluntarily report adverse events to databases.

Examples:

- VAERS (United States)
- EudraVigilance (European Union)
- VigiBase (WHO global database)

Active Surveillance

Authorities actively monitor vaccinated individuals through follow-up studies and electronic health records.

Cohort Event Monitoring

Specific groups of vaccinated individuals are observed over time to study vaccine safety.

Post-Marketing Surveillance

Monitoring continues after vaccine approval to identify rare adverse effects not detected during clinical trials.

Global Organizations Involved in Pharmacovigilance

- World Health Organization
- Uppsala Monitoring Centre
- Food and Drug Administration
- European Medicines Agency

These organizations coordinate global vaccine safety monitoring and data sharing.

Conclusion

Pharmacovigilance is a crucial component of COVID-19 vaccine safety monitoring. It helps identify adverse events, evaluate risks, and ensure that vaccines remain safe and effective for the global population. Continuous surveillance, international cooperation, and transparent communication are essential principles that strengthen public trust in vaccination programs and support global public health.

VI. Global Safety Monitoring Systems for COVID-19 Vaccines

Global safety monitoring systems for COVID-19 vaccines are coordinated networks used by health authorities to detect, assess, and respond to possible vaccine side effects after vaccines are approved and widely distributed. These systems combine **passive surveillance** (spontaneous reporting of adverse events) and **active surveillance** (systematic analysis of health records and databases).

Major Global Safety Monitoring Systems

1. World Health Organization (WHO) Pharmacovigilance Network

The World Health Organization coordinates global vaccine safety monitoring through the WHO Programme for International Drug Monitoring.

Key components include:

- **VigiBase** – the world's largest database of suspected adverse drug reactions, maintained by the Uppsala Monitoring Centre in Sweden.
- National regulatory agencies from over 140 countries submit adverse event reports.

- WHO's Global Advisory Committee on Vaccine Safety (GACVS) evaluates emerging safety signals.

WHO collects reports from countries and looks for unusual patterns that might indicate rare side effects requiring investigation.

2. United States Monitoring Systems

The Centers for Disease Control and Prevention and Food and Drug Administration operated multiple complementary systems during the COVID-19 vaccination campaign.

Passive Surveillance

VAERS (Vaccine Adverse Event Reporting System)
Anyone—including healthcare professionals and patients—can report health problems occurring after vaccination. VAERS serves as an "early warning" system.

Active Surveillance

- **V-safe**
  Smartphone-based monitoring where vaccinated individuals reported symptoms after vaccination.
- **Vaccine Safety Datalink (VSD)**
  Uses electronic health records from healthcare organizations to identify and study rare adverse events.
- **BEST (Biologics Effectiveness and Safety System)**
  FDA system using claims and electronic health records for near real-time surveillance.
- **CISA (Clinical Immunization Safety Assessment Project)**
  Expert network investigating complex vaccine safety questions.

These systems helped identify very rare adverse effects such as:

- Myocarditis after mRNA vaccines
- Thrombosis with thrombocytopenia syndrome (TTS) after adenoviral vector vaccines
- Guillain–Barré syndrome in rare cases

3. European Union Monitoring Systems

The European Medicines Agency oversees vaccine safety in the EU and EEA.

Important systems include:

- **EudraVigilance** – EU database for suspected adverse reactions
- Continuous review by EMA's Pharmacovigilance Risk Assessment Committee (PRAC)
- Monthly and periodic safety update reports from vaccine manufacturers

EMA continuously analyzes:

- Clinical studies
- Scientific literature
- Electronic healthcare databases
- Reports from patients and healthcare professionals

4. National Pharmacovigilance Systems Worldwide

Many countries maintain their own surveillance systems linked to WHO networks.

Examples:

- Medicines and Healthcare products Regulatory Agency – Yellow Card Scheme
- Health Canada – Canadian Adverse Events Following Immunization Surveillance System
- Therapeutic Goods Administration – AusVaxSafety
- Central Drugs Standard Control Organization – Adverse Events Following Immunization (AEFI) surveillance

How These Systems Work Together

The monitoring process generally follows this sequence:

1. Vaccination occurs
2. Adverse events are reported
3. Databases detect unusual patterns ("safety signals")
4. Scientists investigate whether the vaccine likely caused the event
5. Regulators update guidance, warnings, or recommendations if needed

This global system enabled rapid identification of rare side effects during the pandemic while continuing vaccination campaigns.

Important Limitation of Reporting Systems

A reported adverse event does **not automatically mean** the vaccine caused the event.

Passive reporting systems like VAERS and EudraVigilance are designed to detect possible signals, not prove causation. Reported events must be scientifically investigated using epidemiological studies and clinical review.

Methods of Safety Surveillance

1. Passive Surveillance (Spontaneous Reporting)

This is the most widely used baseline system.

- Healthcare workers, manufacturers, and the public report adverse events after vaccination.
- Reports are collected in national and global databases.

Examples:

- VAERS (USA)
- VigiBase (global)
- EudraVigilance (EU)

Key feature:

- Early warning system for detecting unusual or rare events.

Limitation:

- Cannot prove cause-effect relationship.

2. Active Surveillance

In this method, health authorities actively collect follow-up data instead of waiting for reports.

Approaches:

- Follow-up surveys after vaccination
- Automated SMS/app-based reporting
- Monitoring electronic health records

Examples:

- v-safe (USA)
- Vaccine Safety Datalink (VSD)

Key feature:

- More accurate and timely than passive systems.

3. Cohort Event Monitoring (CEM)

- Large groups of vaccinated people are followed over time.
- All health events after vaccination are recorded and analyzed.

Use:

- Detects both common and rare side effects in real-world conditions.

4. Sentinel Surveillance

- Selected hospitals or health centers actively monitor vaccine-related adverse events.
- Provides high-quality, detailed clinical data.

Key feature:

- Focused and more accurate than general reporting systems.

5. Electronic Health Record (EHR)–Based Surveillance

- Uses hospital databases and insurance claims.
- Automatically detects patterns of illness after vaccination.

Examples:

- Vaccine Safety Datalink (USA)
- FDA BEST system

6. Signal Detection and Data Mining

Once data is collected, statistical methods are used to identify unusual patterns ("signals").

Techniques:

- Disproportionality analysis
- Bayesian data mining
- Observed vs expected analysis

Purpose:

- To identify rare adverse effects like myocarditis or TTS early.

7. Epidemiological Study Designs (Causality Assessment)

Used after a safety signal is detected.

Common study types:

- Case-control studies
- Cohort studies
- Self-controlled case series (SCCS)

Purpose:

- To determine whether the vaccine actually caused the event.

8. Risk–Benefit Analysis

- Compares vaccine risks with disease risks.
- Helps guide public health policy decisions.

Summary Flow (Simple)

1. Vaccination occurs
2. Data collected (passive + active systems)
3. Signals detected (statistical monitoring)
4. Scientific studies confirm or reject risk

5. Health authorities update guidelines

✔ Adverse Events Associated with COVID-19 Vaccines

COVID-19 vaccines have been extensively monitored worldwide through pharmacovigilance systems. Most side effects are mild and temporary, while serious adverse events are rare.

1. Common (Mild) Adverse Events

These usually occur within 1–3 days after vaccination and resolve without treatment.

- Pain at injection site
- Redness and swelling
- Fever
- Fatigue
- Headache
- Muscle and joint pain
- Chills
- Nausea

These reactions indicate activation of the immune system.



2. Less Common Adverse Events

These occur in a smaller number of individuals:

- Swollen lymph nodes (lymphadenopathy)

- Persistent fever
- Allergic reactions (mild to moderate)
- Dizziness
- Rapid heartbeat in some cases

3. Rare but Serious Adverse Events

These are closely monitored by global safety systems.

a) Myocarditis and Pericarditis

- Mostly reported in younger males after mRNA vaccines
- Inflammation of heart muscle or surrounding tissue
- Usually mild and recoverable with treatment

b) Thrombosis with Thrombocytopenia Syndrome (TTS)

- Very rare clotting disorder associated mainly with viral vector vaccines
- Includes blood clots with low platelet count

c) Severe Allergic Reactions (Anaphylaxis)

- Occurs shortly after vaccination
- Requires immediate medical care
- Extremely rare (a few cases per million doses)

d) Guillain–Barré Syndrome (GBS)

- Rare neurological condition affecting nerves
- Reported in small numbers after some vaccines

e) Myocardial Events in High-Risk Individuals

- Observed mostly in people with pre-existing conditions, but causal link varies

4. Very Rare or Investigational Events

These are still under continuous study:

- Menstrual cycle changes (temporary irregularities reported by some individuals)
- Reactivation of herpes zoster (shingles) in some cases
- Neurological symptoms (under investigation in pharmacovigilance databases)

5. Key Global Findings

- Most vaccines show a strong safety profile
- Benefits of vaccination significantly outweigh risks
- Rare events are detected through systems like:
  - VAERS
  - EudraVigilance

✔ Role of International Organizations and Regulatory Authorities in COVID-19 Vaccine Safety Surveillance

The safety of COVID-19 vaccines is ensured through a coordinated global system involving international organizations and national regulatory authorities. These bodies work together to monitor adverse events, assess risks, and maintain public trust in vaccination programs.

1. World Health Organization (WHO)

The World Health Organization plays a central role in coordinating global vaccine safety.

Key roles:

- Coordinates international vaccine safety monitoring through the Global Advisory Committee on Vaccine Safety (GACVS)
- Maintains global pharmacovigilance through the VigiBase system (via Uppsala Monitoring Centre)
- Provides technical guidelines for detecting and assessing adverse events following immunization (AEFI)
- Supports low- and middle-income countries in building vaccine safety systems
- Issues global safety communications when risks are identified

Importance:

WHO ensures that vaccine safety data is shared globally, allowing early detection of rare adverse events across countries.

2. United States Regulatory Authorities

The United States has a multi-layered surveillance system led by:

- Centers for Disease Control and Prevention (CDC)
- Food and Drug Administration (FDA)

Key roles:

- Monitoring vaccine safety through systems like VAERS, V-safe, and Vaccine Safety Datalink (VSD)
- Conducting real-time data analysis for adverse event detection
- Investigating potential safety signals (e.g., myocarditis, TTS)
- Updating vaccine recommendations based on risk–benefit analysis
- Authorizing vaccines for emergency or full use after safety evaluation

Importance:

These agencies ensure continuous safety evaluation even after vaccine approval.

3. European Medicines Agency (EMA)

The European Medicines Agency regulates vaccine safety across the European Union.

Key roles:

- Monitors vaccine safety through EudraVigilance
- Evaluates periodic safety reports from manufacturers
- Reviews data through the Pharmacovigilance Risk Assessment Committee (PRAC)
- Issues safety updates and warnings when necessary
- Coordinates with national EU regulatory bodies

Importance:

EMA ensures harmonized vaccine safety monitoring across all EU member states.

4. National Regulatory Authorities

Each country has its own pharmacovigilance system linked to global networks.

Examples:

- Medicines and Healthcare products Regulatory Agency (UK)
- Health Canada
- Therapeutic Goods Administration (Australia)
- Central Drugs Standard Control Organization (India)

Key roles:

- Collect and analyse Adverse Events Following Immunization (AEFI)
- Report safety data to WHO global systems
- Implement national vaccine safety guidelines
- Conduct local investigations and public communication

5. Uppsala Monitoring Centre (UMC)

The Uppsala Monitoring Centre supports WHO's global database.

Key roles:

- Manages VigiBase, the world's largest adverse event database
- Uses advanced data mining to detect safety signals
- Supports countries in pharmacovigilance capacity building

6. Coordination Mechanism Between Agencies

Global vaccine safety works through a structured system:

1. Countries report adverse events
2. Data is shared with WHO and regional systems

3. Statistical tools identify unusual patterns
4. Regulatory agencies investigate signals
5. Safety recommendations are updated globally

Challenges in Global Pharmacovigilance

Global pharmacovigilance refers to the detection, assessment, understanding, and prevention of adverse effects of medicines and vaccines across countries. During the COVID-19 vaccination program, large-scale monitoring systems worked effectively, but several challenges were also identified.

1. Underreporting of Adverse Events

One of the most significant challenges is that many adverse events are never reported.

- Mild or delayed symptoms are often ignored by patients
- Healthcare workers may not report every case due to workload
- Reporting systems rely heavily on voluntary submissions

Impact:
This leads to incomplete data and may delay detection of safety signals.

2. Data Quality and Inconsistency

Reports submitted to global databases often vary in quality.

- Missing clinical details
- Incomplete patient history
- Differences in diagnostic standards between countries
- Duplicate or unverified reports

Impact:
Makes it difficult to analyze true vaccine-related risks accurately.

3. Lack of Standardization Across Countries

Different countries use different definitions and reporting formats for adverse events.

- Variation in what is considered “serious”
- Different surveillance tools and coding systems
- Unequal regulatory frameworks

Impact:
Limits comparability of data at the global level.

4. Causality Assessment Difficulties

A major scientific challenge is determining whether a vaccine actually caused an event.

- Many adverse events occur naturally in the population
- Temporal association does not mean causation
- Confounding factors like age, disease, or comorbidities

Impact:
Requires complex epidemiological studies, which take time.

5. Limited Infrastructure in Low- and Middle-Income Countries

Some countries face resource constraints.

- Weak reporting systems
- Lack of trained pharmacovigilance professionals
- Poor digital health infrastructure
- Limited laboratory and diagnostic capacity

Impact:
Leads to delayed or incomplete safety monitoring.

6. Data Overload During Mass Vaccination

During COVID-19, billions of doses were administered in a short time.

- Massive increase in reported events
- Difficulty distinguishing true signals from background noise
- Strain on regulatory agencies

Impact:

Slows down analysis and prioritization of safety signals.

7. Public Misinterpretation and Misinformation

Safety data is often misunderstood by the public.

- Misinterpretation of raw adverse event reports
- Spread of misinformation on social media
- Confusion between correlation and causation

Impact:

Reduces vaccine confidence and increases hesitancy.

8. Delayed Signal Detection in Rare Events

Rare adverse events may take time to identify.

- Require large datasets and long observation periods
- Early signals may be weak or inconsistent

Impact:

Delay in confirming extremely rare side effects.

9. Privacy and Data Sharing Restrictions

- Strict data protection laws in many countries
- Limited sharing of patient-level data across borders

Impact:

Restricts global collaboration and detailed analysis

Recent Advances in COVID-19 Vaccine Pharmacovigilance

Pharmacovigilance for COVID-19 vaccines has rapidly evolved due to the global scale of vaccination and the need for real-time safety monitoring. Recent advances focus on digital technology, artificial intelligence, integrated health data systems, and stronger international collaboration.

1. Real-Time Digital Surveillance Systems

Modern pharmacovigilance has shifted from delayed reporting to near real-time monitoring.

- Electronic reporting platforms allow instant submission of adverse events
- Automated dashboards track safety signals continuously
- Integration with hospital and national health systems improves speed of detection

Example systems:

- VAERS upgraded digital reporting interfaces
- EU's EudraVigilance real-time signal monitoring

2. Use of Artificial Intelligence and Machine Learning

AI-based tools are increasingly used to analyze large safety datasets.

- Detect hidden patterns in adverse event reports
- Predict potential safety signals earlier than traditional methods
- Reduce false positives from large datasets

Impact:

Improves speed and accuracy of signal detection.

3. Big Data Integration from Electronic Health Records (EHRs)

Health systems now use large-scale clinical databases for vaccine monitoring.

- Combines hospital records, insurance claims, and laboratory data
- Enables comparison of vaccinated vs unvaccinated populations
- Supports rapid epidemiological studies

Examples:

- Vaccine Safety Datalink (VSD)
- FDA BEST system

4. Active Surveillance via Mobile and Digital Tools

Digital health tools allow direct reporting from vaccine recipients.

- Smartphone-based symptom tracking
- SMS and app-based follow-ups after vaccination
- Automated reminders for reporting symptoms

Example:

- v-safe

5. Global Data Sharing and Collaboration

COVID-19 led to stronger international cooperation in pharmacovigilance.

- Faster sharing of safety signals between countries
- WHO coordination through global databases
- Harmonized reporting standards improving comparability

Key platform:

- World Health Organization global pharmacovigilance network

6. Advanced Signal Detection Methods

Modern statistical techniques are now widely used.

- Bayesian data mining
- Disproportionality analysis
- Self-controlled case series (SCCS) methods

Impact:
Helps identify rare adverse events such as myocarditis or thrombosis earlier.

7. Integration of Genomic and Personalized Risk Analysis

New research explores how genetics may influence vaccine reactions.

- Identification of high-risk groups based on biological markers
- Personalized vaccine safety assessment in future systems

8. Improved Transparency and Public Dashboards

Regulatory agencies now publish vaccine safety data openly.

- Public dashboards showing adverse event trends
- Regular safety updates from regulatory authorities
- Improved communication to reduce misinformation

9. Strengthened Post-Marketing Surveillance Frameworks

Regulators have improved post-approval monitoring systems.

- Continuous safety review even after emergency approval
- Faster regulatory action when safety signals appear
- Stronger manufacturer reporting requirements

Case Studies and Global Reports in COVID-19 Vaccine Pharmacovigilance

COVID-19 vaccine safety monitoring has been supported by large international databases and multiple real-world case studies. These studies help identify rare adverse events, evaluate vaccine safety, and guide regulatory decisions.

1. Myocarditis and Pericarditis after mRNA Vaccines

One of the most widely studied safety signals is myocarditis and pericarditis, particularly after mRNA vaccines.

Key findings:

- Higher incidence in young males, especially after the second dose
- Most cases are mild and recover with treatment
- Strong surveillance signals detected in Europe and North America

Evidence from Europe:

Analysis from the European adverse event database reported thousands of suspected cases of myocarditis and pericarditis, with higher frequency in males aged 18–24 years.

Interpretation:

Regulatory agencies concluded that while there is a small increased risk, the benefits of vaccination outweigh the risks.

2. Global Safety Data from EudraVigilance (EU Report)

The EudraVigilance system collected millions of reports during the pandemic.

Key observations:

- High number of reports after mass vaccination campaigns
- Majority of reactions were mild (fever, fatigue, injection-site pain)
- Rare serious events included thrombosis and myocarditis

Regulatory action:

The European Medicines Agency continuously reviewed these signals and updated vaccine guidance when needed.

3. VAERS-Based Signal Detection (United States)

The VAERS system played a major role in early detection of vaccine safety signals.

Key findings:

- Early identification of rare adverse events such as myocarditis
- Large increase in reporting volume during COVID-19 vaccination rollout
- Data used as an early warning system, not proof of causation

Important limitation:

Reports in VAERS are unverified and require further epidemiological study to confirm causality.

4. VigiBase Global Pharmacovigilance Report

The World Health Organization maintains the global database VigiBase.

Key contributions:

- Aggregates reports from over 140 countries
- Enables global signal detection across populations
- Helps identify rare events that may not appear in single-country data

Example:

VigiBase analyses contributed to monitoring rare events such as thrombosis with thrombocytopenia syndrome (TTS) linked to adenoviral vector vaccines.

5. Thrombosis with Thrombocytopenia Syndrome (TTS)

A major global case study involved adenoviral vector vaccines (e.g., AstraZeneca and Johnson & Johnson).

Findings:

- Extremely rare but serious clotting disorder
- Occurred mostly in younger adults, especially women
- Early detection came from combined national reports across Europe and the UK

6. Large Population Studies

Large observational studies involving millions of individuals were conducted in Europe, North America, and Asia.

Key results:

- No increase in long-term mortality after vaccination
- Strong protection against severe COVID-19 outcomes
- Rare adverse events detected but at very low frequency

Example:

A large French cohort study involving over 28 million people found no increased long-term mortality among vaccinated individuals and confirmed overall vaccine safety.

7. Global WHO Safety Communication Reports

The World Health Organization issued regular safety updates during the pandemic.

Key functions:

- Coordination of international safety alerts
- Guidance to national regulatory agencies
- Standardization of adverse event classification

VII. Understanding how antiviral antibodies can activate natural killer cells to improve viral control

Antiviral antibodies can improve viral control not only by neutralizing viruses directly, but also by recruiting and activating **natural killer (NK) cells**, a major component of the innate immune system. This cooperation between antibodies and NK cells is an important bridge between adaptive and innate immunity.

How antiviral antibodies activate NK cells

When a virus infects a cell, viral proteins appear on the infected cell surface. Antiviral antibodies produced by B cells bind to these viral antigens. The antibody-coated infected cell can then be recognized by NK cells through a receptor called CD16 (FcγRIII) on the NK-cell surface.

Antibody-dependent cellular cytotoxicity (ADCC)

1. Antibodies attach to virus-infected cells.
2. NK cells bind to the Fc portion of these antibodies via CD16.
3. NK cells become activated and release toxic molecules such as:
    - Perforin — creates pores in target cells
    - Granzymes — enter through pores and induce apoptosis
4. The infected cell is destroyed before the virus can spread further.



The epidemiology of COVID-19 in Ugandan settlements and neighbouring communities

The epidemiology of COVID-19 in Ugandan refugee settlements and neighbouring host communities provides an important case study of how infectious diseases spread in vulnerable, resource-limited, and highly mobile populations.

Uganda hosts one of the largest refugee populations in Africa, with around 1.4–1.5 million refugees, primarily from South Sudan and the Democratic Republic of the Congo. Most refugees live in settlements integrated with Ugandan host communities rather than isolated camps, creating unique epidemiological dynamics.



Screening antiviral drugs against the envelope (E) protein of SARS-CoV-2

The **envelope (E) protein** of COVID-19-causing SARS-CoV-2 is a small structural protein that plays a major role in viral assembly, budding, pathogenesis, and host-cell interactions. Because it is highly conserved and functionally important, researchers have investigated it as a target for antiviral drug screening.

What is the SARS-CoV-2 E protein?

- A small membrane protein (~75 amino acids)
- Located in the viral envelope
- Involved in:
- Virus assembly and release
- Membrane curvature

- Virulence
- Ion transport activity

VIII. Recent Advances in Pharmacovigilance

Pharmacovigilance (PV) has improved significantly in recent years due to advances in technology, data science, and global healthcare systems. These developments help in faster detection and prevention of adverse drug reactions (ADRs).

1. Artificial Intelligence (AI) in PV

AI and machine learning are now used to identify safety signals, detect duplicate reports, and automate adverse event processing. These tools improve accuracy and reduce manual workload.

2. Use of Real-World Evidence (RWE)

Real-world data from electronic health records, insurance claims, and patient registries are increasingly used to evaluate drug safety in actual clinical practice.

3. Electronic and Mobile ADR Reporting

Digital reporting systems, mobile applications, and QR-code-based reporting methods have simplified ADR submission by healthcare professionals and patients.

4. Big Data and Data Mining

Advanced data mining techniques help analyze large safety databases quickly and identify hidden patterns related to adverse drug reactions.

5. Improved Signal Detection Systems

Modern PV systems use automated signal detection tools that identify potential drug safety risks earlier than traditional methods.

6. Integration of Pharmacogenomics

Pharmacogenomics studies how genetic differences affect drug responses. This helps in predicting adverse reactions and supports personalized medicine.

7. Global Harmonization

International organizations are working to standardize reporting systems and safety guidelines, improving global sharing of pharmacovigilance data.

8. Natural Language Processing (NLP)

NLP technology can extract safety information from medical literature, social media, and clinical notes more efficiently.

9. Advanced Safety Databases

Modern safety databases such as automated adverse event management systems allow faster case processing and regulatory reporting.

10. Focus on Biologics and Vaccines

Specialized monitoring systems are now used for biologics, biosimilars, and vaccines to ensure better safety surveillance in complex.

IX. Conclusion

In conclusion, the global pharmacovigilance system for COVID-19 vaccines has proven to be highly effective in ensuring vaccine safety during an unprecedented worldwide vaccination campaign. The integration of international collaboration, advanced digital surveillance systems, and continuous regulatory oversight enabled early detection and management of rare adverse events.

X. Results

Results of the Project

The study of **global safety monitoring systems for COVID-19 vaccines** shows that an extensive and well-structured pharmacovigilance network was implemented worldwide to ensure vaccine safety.

- Multiple surveillance systems such as passive reporting systems, active follow-up systems, and electronic health record–based monitoring were used effectively.
- International organizations like the World Health Organization, EMA, CDC, and national regulatory authorities successfully coordinated vaccine safety monitoring across countries.
- Most reported adverse events were **mild and temporary**, including fever, fatigue, headache, and injection-site pain.

- Rare but serious adverse events such as **myocarditis, pericarditis, thrombosis with thrombocytopenia syndrome (TTS), and anaphylaxis** were identified through global monitoring systems.
- Advanced tools such as real-time databases, AI-based signal detection, and big data analytics improved the speed and accuracy of safety assessments.
- Global case studies and reports confirmed that although rare adverse events exist, they are significantly outweighed by the benefits of vaccination in preventing severe COVID-19 illness, hospitalization, and death.

References

1. Rudolph A., Mitchell J., Barrett J., et al. *Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge.* Therapeutic Advances in Drug Safety, 2022.
2. WHO. *Pharmacovigilance of COVID-19 vaccines.*
3. Caplanusi I., et al. *The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines.* Drug Safety, 2024.
4. Oliveira M.M.M., et al. *Pharmacovigilance quality system for vaccine monitoring (COVID-19): a scoping review.* International Journal of Infection Control.
5. Turfah A., Wen X., Zhao L. *Non-parametric Bayesian mixture model to study adverse events of COVID-19 vaccines.*
6. Zhao B., Zhong Y., Kang J., Zhao L. *Bayesian learning of COVID-19 vaccine safety while incorporating adverse event ontology.*
7. Mahurkar, R. N., et al. (2025). *Analysis of adverse event reporting patterns following COVID-19 vaccination.* International Journal of Basic & Clinical Pharmacology. https://www.ijbcp.com/index.php/ijbcp/article/view/6009
8. Tan, Y., et al. (2026). *A review of statistical methods for spontaneous reporting system data mining.* arXiv. https://arxiv.org/abs/2604.18898
9. Klein, N. P., et al. (2021). *Surveillance for COVID-19 vaccine safety.* New England Journal of Medicine.
10. World Health Organization. (2020). *COVID-19 vaccines: Safety surveillance manual.* https://www.who.int/publications/i/item/10665338400
11. Uppsala Monitoring Centre (WHO Collaborating Centre). *VigiBase – Global pharmacovigilance database.* https://who-umc.org/vigibase/

12. World Health Organization. *Global Advisory Committee on Vaccine Safety (GACVS).* https://www.who.int/groups/global-advisory-committee-on-vaccine-safety
13. https://www.nejm.org/doi/full/10.1056/NEJMra2035343
14. European Medicines Agency (EMA). *Safety of COVID-19 vaccines.* https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines
15. EudraVigilance – European database of suspected adverse reactions. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance/eudravigilance
16. Centers for Disease Control and Prevention (CDC). *COVID-19 Vaccine Safety Monitoring Systems.* https://www.cdc.gov/vaccine-safety-systems/monitoring/covid-19.html
17. Vaccine Adverse Event Reporting System (VAERS). https://vaers.hhs.gov/
18. U.S. Food and Drug Administration (FDA). *COVID-19 Vaccine Safety Surveillance.* https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/covid-19-vaccine-safety-surveillance
19. Indian Pharmacopoeia Commission (IPC). *PvPI – Pharmacovigilance Programme of India.* https://www.ipc.gov.in/PvPI.html
20. Central Drugs Standard Control Organization (CDSCO). https://cdsco.gov.in/
21. Rudolph A., Mitchell J., Barrett J., et al. *Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge.* Therapeutic Advances in Drug Safety, 2022.
22. WHO. *Pharmacovigilance of COVID-19 vaccines.*
23. Caplanusi I., et al. *The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines.* Drug Safety, 2024.
24. Oliveira M.M.M., et al. *Pharmacovigilance quality system for vaccine monitoring (COVID-19): a scoping review.* International Journal of Infection Control.
25. Turfah A., Wen X., Zhao L. *Non-parametric Bayesian mixture model to study adverse events of COVID-19 vaccines.*
26. Zhao B., Zhong Y., Kang J., Zhao L. *Bayesian learning of COVID-19 vaccine safety while incorporating adverse event ontology.*
27. Pertwee E, Simas C and Larson HJ. An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy. Nat Med 2022; 28: 456–459.

28. 2. Li Y-D, Chi W-Y, Su J-H, et al. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci 2020; 27: 104.
29. 3. Wang Z, Yuan Z, Matsumoto M, et al. Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice. Biochem Biophys Res Commun 2005; 327: 130–135.
30. Munoz FM, Cramer JP, Dekker CL, et al. Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2021; 39: 3053–3066.
31. Bok K, Sitar S, Graham BS, et al. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity 2021; 54: 1636–1651.
32. London School of Hygiene & Tropical Medicine. Vaccine landscape, https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/# (2021, accessed 8 May 2021).
33. Regulatory Affairs Professionals Society. COVID_19 vaccine tracker. J Craven, https://www.raps.org/news-and-articles/newsarticles/2020/3/covid-19-vaccine-tracker (18 February 2021, accessed 23 February 2021).
34. World Health Organization. COVID-19 – landscape of novel coronavirus candidate vaccine development worldwide, https://www.who.int/publications/m/item/draft-landscape-of-covid-19candidate-vaccines (2021, accessed 8 October 2021).
35. European Medicines Agency. EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines, https://www.ema.europa.eu/en/documents/other/ema-initiatives-accelerationdevelopment-support-evaluation-procedurescovid-19-treatments-vaccines_en.pdf (2021, accessed 8 March 2021).
36. Maraqa B, Nazzal Z, Rabi R, et al. COVID-19 vaccine hesitancy among health care workers in Palestine: a call for action. Prev Med 2021; 149: 106618.
37. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021; 27: 225–228. 12. Black S, Eskola J, Siegrist C-A, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009; 374: 2115–2122.
38. Sharma O, Sultan AA, Ding H, et al. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 2020; 11: 585354.
39. World Health Organization. COVID-19 vaccines: safety surveillance mannual, https://apps.who.int/iris/bitstream/handle/10665/338400/9789240018280journals.sagepub.com/home/taw

40. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
41. 2. Dhama K, Patel SK, Sharun K, et al. SARS-CoV-2 jumping the species barrier: zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel Med Infect Dis. 2020;37:101830.
42. 3. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect. 2020;S1684–182(20):30082–7.
43. 4. Malik YS, Kumar N, Sircar S, et al. Coronavirus disease pandemic (COVID-19): challenges and a global perspective. Pathogens. 2020;9(7):519.
44. Shadmi E, Chen Y, Dourado I, et al. Health equity and COVID-19: global perspectives. Int J Equity Health. 2020;19(1):1–16.
45. Paniz-Mondolfi AE, Sordillo EM, Marquez-Colmenarez MC, et al. The arrival of SARS-CoV-2 in venezuela. Lancet. 2020;395(10):e85–6.
46. Bonilla-Aldana DK, Villamil-Gómez WE, Rabaan AA, et al. Una nueva zoonosis viral de preocupación global: COVID-19, enfermedad por coronavirus 2019. Iatreia. 2020;33(2):107–10.
47. World Health Organization. WHO coronavirus disease (COVID19) Dashboard. 2021. https:// covid 19. who. int/. Accessed 3 Jul 2021.
48. Choudhary OP, Priyanka Singh I, Rodriguez-Morales AJ. Second wave of COVID-19 in India: dissection of the causes and lessons learnt. Travel Med Infect Dis. 2021;43:102126.
49. Shahid Z, Kalayanamitra R, McClafferty B, et al. COVID-19 and older adults: what we know. J Am Geriatr Soc. 2020;68(5):926–9. 11. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
50. Patel SK, Singh R, Rana J, et al. The kidney and COVID-19 patients—important considerations. Travel Med Infect Dis. 2020;37:101831.
51. Wang J, Peng Y, Xu H, et al. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech. 2020;21(6):225.
52. Patel SK, Pathak M, Tiwari R, et al. A vaccine is not too far for COVID-19. J Infect Dev Ctries. 2020;14(5):450–3.
53. Rabaan AA, Al-Ahmed SH, Sah R, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Ann Clin Microbiol Antimicrob. 2020;19(1):40.
54. McGill COVID19 Vaccine Tracker Team. 2021. Vaccines Candidates by Trial Phase. https:// covid 19. track vacci nes. org/ vacci nes/? fbclid= IwAR0 rJdUx 1T1j9 TalYC Jzwvn qm6MW luN2w wWtnu DP0GW 6YvKL h3nW- Ex0ZKU. Accessed 27 June 2021.